MedTrace Logo

The Role of Intra-articular Injection of PRP Versus Corticosteriods in Treatment of Lumbar Facet Disease

NCT04860531 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-05-04

No results posted yet for this study

Summary

Low back pain is an extremely common health problem and recent studies have shown that nearly up to 52% of patients have low back pain caused by lumbar facet joint syndrome. Intra-articular injection of facet joints has gradually become one of the vital therapeutic methods for lumbar facet joint syndrome, Steroid is one of the most commonly used injected drugs; however, previous studies have indicated that it has limited ability in long-term relief of low back pain. Therefore, it seems meaningful to apply a new injectable drug and to prove its effectiveness and safety for the treatment of lumbar facet joint syndrome. Recent studies indicate that autologous platelet rich plasma(PRP) is an appropriate injectable material with great potential in treating many different musculoskeletal disorders and currently it is not yet used on a wide scale as a treatment for lumbar facet joint synovitis. In this study the investigators compare the efficacy and safety of Intra-articular injection of PRP versus conventional steriods in patients with lumbar facet joint synovitis.

Conditions

  • Lumbar Facet Joint Syndrome

Interventions

DRUG

Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma

Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints

DRUG

Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone

Lumbar Facet Joints intra-articular injection

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Nahed Monir, Professor · Faculty of Medicine Ain Shams University

  • Hala Abdelhady, Professor · Faculty of Medicine Ain Shams University

  • Sahar Fathy, Professor · Faculty of Medicine Ain Shams University

  • Hossam Sakr · Faculty of Medicine Ain Shams University

  • Mohamed Taeimah, MD · Faculty of Medicine Ain Shams University

  • Shahdan Kotb · Faculty of Medicine Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2021-01-22
Completion
2021-01-22

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04860531 on ClinicalTrials.gov